Skip to Content

Fosaprepitant Dosage

Medically reviewed on January 10, 2018.

Applies to the following strengths: 150 mg; 115 mg

Usual Adult Dose for Nausea/Vomiting - Chemotherapy Induced

150 mg IV over 20 to 30 minutes approximately 30 minutes before chemotherapy on Day 1

Highly Emetogenic Cancer Chemotherapy:
-Day 1: Dexamethasone 12 mg orally 30 minutes prior to chemotherapy; 5-HT3 antagonist orally/IV per treatment guidelines
-Day 2: Dexamethasone 8 mg orally once a day in the morning
-Days 3 and 4: Dexamethasone 8 mg orally two times a day

Moderately Emetogenic Cancer Chemotherapy:
Day 1: Dexamethasone 12 mg orally 30 minutes prior to chemotherapy; 5-HT3 antagonist orally/IV per treatment guidelines

-The 5-HT3 antagonists studied with this drug include ondansetron, granisetron, and dolasetron. Dosage should be determined by accepted treatment guidelines.

Uses: Prevention, in combination with other antiemetic drugs, of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (including high-dose cisplatin) and moderately emetogenic cancer chemotherapy

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Mild to moderate liver dysfunction (Child-Pugh 5 to 9): No adjustment recommended.
Severe liver dysfunction (Child-Pugh greater than 9): Use with caution.

Dose Adjustments

Geriatric Patients:
-Use with caution, as age-related hepatic, renal or cardiac function decreases and/or concomitant disease/other drug therapy may interact with therapy.


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


No adjustment recommended.

Other Comments

Administration advice:
-Always administer therapy as a diluted, slow IV infusion over at least 20 to 30 minutes.
-This drug should not be given as a bolus injection or via IM/subcutaneous routes.
-Pretreatment with a corticosteroid and antiemetic agent should begin at least 30 minutes prior to beginning chemotherapy.

Storage requirements:
-The manufacturer product information should be consulted.

Reconstitution/preparation techniques:
-The manufacturer product information should be consulted.

IV compatibility:
-The manufacturer product information should be consulted.

-This drug has not been studied in the treatment of established nausea and vomiting.
-The AUC of dexamethasone increased by 100% when administered with this drug. Lower doses of dexamethasone are recommended for use in the treatment of highly emetogenic cancer chemotherapy on days 1 and 2 account for this interaction.

-Injection site reactions, including irritation and thrombosis
-Hypersensitivity reactions at any time during treatment
-INR in patients taking warfarin, especially 7 to 10 days after beginning this drug at each cycle

Patient advice:
-Patients should be advised to report all concurrent prescription and nonprescription medications or herbal products they are taking.
-Instruct patients to immediately report any signs/symptoms of Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity reactions.
-Patients should be advised to speak to healthcare provider if pregnant, intend to become pregnant, or are breastfeeding; patients using hormonal contraception to prevent pregnancy will need to speak with their health care provider about using a non-hormonal back-up method of birth control for up to 2 months after completing therapy.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.